- Trials with a EudraCT protocol (46)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
46 result(s) found for: Interleukin 25.
Displaying page 1 of 3.
EudraCT Number: 2021-000200-38 | Sponsor Protocol Number: VitDM3BH | Start Date*: 2021-06-13 |
Sponsor Name:University Clinic of Dentistry, Medical University of Vienna | ||
Full Title: THE IMPACT OF VITAMIN D3 HIGH DOSES SUPPLEMENTATTION ON SOFT TISSUE WOUND-HEALING AFTER MANDIBULAR THIRD MOLAR (M3) REMOVAL: A PILOT STUDY | ||
Medical condition: Vitamin D insufficiency undergoing tooth extraction | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002476-13 | Sponsor Protocol Number: 20HH5958 | Start Date*: 2020-07-24 | ||||||||||||||||||||||||||
Sponsor Name:Imperial College London | ||||||||||||||||||||||||||||
Full Title: A study to assess the safety and efficacy of Clazakizumab in patients with COVID-19 and kidney disease. | ||||||||||||||||||||||||||||
Medical condition: Patients with kidney disease who are hospitalised with COVID-19 infection with pulmonary involvement (i.e. consistent chest imaging abnormalities) and clinical deterioration (i.e increasing oxygen ... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006637-19 | Sponsor Protocol Number: CARDIOL100-002 | Start Date*: 2022-12-01 | |||||||||||
Sponsor Name:Cardiol Therapeutics Inc. | |||||||||||||
Full Title: Impact of CardiolRxTM on Myocardial Recovery in Patients with Acute Myocarditis A double-blind, placebo-controlled trial (ARCHER) | |||||||||||||
Medical condition: Acute Myocarditis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019952-35 | Sponsor Protocol Number: CS001P3 | Start Date*: 2010-09-14 |
Sponsor Name:CEL-SCI Corporation | ||
Full Title: A Phase III, Open-label, Randomized, Multi-center Study of the Effects of Leukocyte Interleukin, Injection [Multikine] Plus Standard of Care (Surgery + Radiotherapy or Surgery + Concurrent Chemorad... | ||
Medical condition: Subjects with Advanced Primary Sqamous Cell Carcinoma of the oral Cavity/Soft Palate | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) PL (Completed) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) RO (Ongoing) HR (Completed) ES (Prematurely Ended) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-004554-34 | Sponsor Protocol Number: 2014-004554-34 | Start Date*: 2015-10-15 | |||||||||||
Sponsor Name:Bispebjerg Hospital | |||||||||||||
Full Title: An open label, explorative pharmacokinetic trial, to investigate the Cytochrome (CYP) CYP3A4, - 2E1 and – 1A2 clearance in Obese – versus Non Obese Children by use of well-tested probes (midazolam,... | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005796-10 | Sponsor Protocol Number: | Start Date*: 2009-04-09 |
Sponsor Name:St. Joseph-Hospital g GmbH | ||
Full Title: Untersuchung zum Effekt einer antibiotischen Therapie mit einem Chinolon der 4. Generation (Moxifloxacin) auf Metalloprotease 9 und Interleukin 6 im Wundsekret bei Patienten mit einem diabetischem ... | ||
Medical condition: Patienten mit einem Diabetes mellitus (Typ-1 und Typ-2) und einem infizierten diabetischen Fußsyndrom. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-002184-22 | Sponsor Protocol Number: NS3 | Start Date*: 2021-05-14 | |||||||||||
Sponsor Name:Athens Medical Society | |||||||||||||
Full Title: A phase II randomized, single-blind dose study to evaluate the safety and efficacy of exosomes overexpressing CD24 in 10^9 dose versus 10^10 dose, for the prevention of clinical deterioration in pa... | |||||||||||||
Medical condition: COVID-19 disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003858-33 | Sponsor Protocol Number: AM0010-301 | Start Date*: 2017-05-12 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Followi... | |||||||||||||
Medical condition: Advanced Metastatic Pancreatic Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) ES (Completed) DE (Completed) BE (Completed) GB (Completed) PL (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002701-26 | Sponsor Protocol Number: 64304500CRD2002 | Start Date*: 2021-01-12 | |||||||||||
Sponsor Name:JANSSEN CILAG INTERNATIONAL NV | |||||||||||||
Full Title: A Phase 2a Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Proof-of-Concept Clinical Study to Evaluate the Safety and Efficacy of JNJ-64304500 as Add-on Therapy to Standa... | |||||||||||||
Medical condition: Active Crohn's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002478-20 | Sponsor Protocol Number: PRECISESTUDY | Start Date*: 2022-03-31 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA DI FERRARA | |||||||||||||
Full Title: IDENTIFICATION OF SYNOVIAL BIOMARKERS OF RESPONSE TO IXEKIZUMAB IN REFRACTORY PSORIATIC ARTHRITIS: THE PRECISE STUDY. | |||||||||||||
Medical condition: PSORIATIC ARTHRITIS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005416-26 | Sponsor Protocol Number: ANSWER | Start Date*: 2014-06-06 |
Sponsor Name:Mario Negri Institute | ||
Full Title: A Prospective, Randomized, Open, Blinded Endpoint (PROBE), Clinical Trial to Assess The Renal and Humoral Effects of Sevelamer Carbonate in Patients with Chronic Kidney Disease and Residual Protein... | ||
Medical condition: Chronic Kidney Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-004511-21 | Sponsor Protocol Number: RC-2007-01 | Start Date*: 2007-08-01 | |||||||||||
Sponsor Name:Queen Mary University London | |||||||||||||
Full Title: Upfront Sunitinib (SU011248)® therapy followed by surgery in patients with metastatic renal cancer: a pilot Phase II study [SuMR] | |||||||||||||
Medical condition: The current standard treatment in patients with metastatic renal cancer includes nephrectomy followed by immune therapy with either interleukin 2 (rIL-2) or interferon (IFN-α). Unfortunately, resp... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000893-68 | Sponsor Protocol Number: LAED001 | Start Date*: 2012-11-15 |
Sponsor Name:Fundació Clinic per a la Recerca Biomèdica | ||
Full Title: Differences in endothelial function amongst Sitagliptin and Liraglutide Users: A randomized, open-label, parallel-group and active controlled trial | ||
Medical condition: type 2 diabetes patients not well controlled at the maximum tolerated dose of metformin | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2006-003567-31 | Sponsor Protocol Number: KPUK0106 | Start Date*: 2007-05-25 | ||||||||||||||||
Sponsor Name:Med. Klinik II, Grosshadern, Klinikum der Universität München | ||||||||||||||||||
Full Title: Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients | ||||||||||||||||||
Medical condition: hypertension metabolic syndrome | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Ongoing) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-003444-30 | Sponsor Protocol Number: C0743T12 | Start Date*: 2007-05-15 | |||||||||||
Sponsor Name:Centocor B.V. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis | |||||||||||||
Medical condition: Moderate to Severe Plaque Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) DE (Completed) BE (Completed) NL (Completed) GB (Completed) AT (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004421-28 | Sponsor Protocol Number: A2171084 | Start Date*: 2006-11-09 | |||||||||||
Sponsor Name: | |||||||||||||
Full Title: A SIX MONTH, OPEN-LABEL OUTPATIENT, RANDOMIZED PARALLEL GROUP TRIAL ASSESSING THE IMPACT OF DRY POWDER INHALED INSULIN (EXUBERA®) ON GLYCEMIC CONTROL COMPARED TO INSULIN GLARGINE (LANTUS®) IN PATIE... | |||||||||||||
Medical condition: Diabetes Mellitus type II (not insulin independent) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) SE (Completed) FR (Completed) BE (Completed) FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005154-57 | Sponsor Protocol Number: CACZ885D2307E1 | Start Date*: 2012-01-03 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: An open-label extension study to assess efficacy, safety and tolerability of canakinumab and the efficacy and safety of childhood vaccinations in patients with Cryopyrin Associated Periodic Syndrom... | |||||||||||||
Medical condition: Cryopyrin Associated Periodic Syndromes (CAPS) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) ES (Completed) DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005332-27 | Sponsor Protocol Number: WA43811 | Start Date*: 2022-01-31 |
Sponsor Name:F. Hoffmann-La Roche Ltd | ||
Full Title: A PHASE Ib, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF TOCILIZUMAB IN PEDIATRIC PATIENTS HOSPITALIZED WITH COVID-19 | ||
Medical condition: Coronavirus disease 2019 (COVID-19) | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Ongoing) IT (Prematurely Ended) GR (Completed) FR (Completed) DE (Completed) PL (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-003388-39 | Sponsor Protocol Number: KDO_DC1311 | Start Date*: 2015-03-26 |
Sponsor Name:Masarykova univerzita | ||
Full Title: COMBINED ANTITUMOR THERAPY WITH EX VIVO MANIPULATED DENDRITIC CELLS PRODUCING INTERLEUKIN-12 IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH PROGRESSIVE, RECURRENT OR PRIMARILY METASTATIC HIGH-RISK ... | ||
Medical condition: Progressive, recurrent or primarily metastatic high-risk malignities | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: CZ (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003497-48 | Sponsor Protocol Number: EMPATHY | Start Date*: 2021-11-29 | |||||||||||
Sponsor Name:Medical University of Warsaw | |||||||||||||
Full Title: Empagliflozin and dapagliflozin in patients hospitalized for acute decompensated heart failure (EMPATHY) – a phase III trial | |||||||||||||
Medical condition: acute decompensated heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
